作为深耕骨科医疗器械领域的标杆企业，爱得科技主营业务涵盖脊柱类、创伤类、运动医学类骨科耗材 及创面修复产品，核心产品已广泛应用于各级医疗机构。此次过会审核中，北交所上市委重点关注了集 采政策对业绩的影响、经销收入真实性等核心问题，公司通过详实数据与合规说明获得监管认可，保荐 机构德邦证券同步出具明确核查意见，验证了公司经营的规范性与信息披露的完整性。 公司拟向不特定合格投资者公开发行股票不少于100万股且不超过2953.0762万股（含本数，不含超额配 售选择权），募集资金1.97亿元将重点投向骨科耗材扩产、研发中心建设及营销网络升级三大项目。在 老龄化加剧带动骨科医疗需求增长的行业背景下，募投项目的落地将进一步扩大公司产能规模，强化技 术研发优势，完善全国性营销布局，为业绩持续增长注入动力。 11月21日，北京证券交易所上市委员会2025年第33次审议会议顺利召开，苏州爱得科技发展股份有限公 司（简称"爱得科技"）首发获审议通过，成为年内第79家北交所过会企业，标志着公司登陆资本市场迈 出关键一步。 （文章来源：证券时报网） ...

Group 1 - The Beijing Stock Exchange and Shanghai Stock Exchange will hold meetings on November 21 to review four IPO applications, all of which have been approved [1] - Aide Technology focuses on orthopedic medical devices, including spinal, trauma, and sports medicine products, aiming to become a leading provider in the domestic market [2] - The company has developed multiple core technologies and holds 110 patents, including 45 invention patents, and has received various recognitions as a high-tech enterprise [2][9] Group 2 - The IPO will be sponsored by Debon Securities, with a total share capital of approximately 88.59 million shares, planning to issue up to 29.53 million shares [3] - The major shareholders are Lu Qiang and Huang Meiyu, who together control 79.07% of the company [4] - The company aims to raise 197 million yuan for three major projects, including orthopedic consumables expansion and R&D center construction [6] Group 3 - Financial data shows total assets of approximately 652 million yuan as of June 30, 2025, with a net profit of about 38.22 million yuan for the first half of 2025 [5] - The company has maintained a low debt ratio, with a debt-to-asset ratio of 13.07% as of June 30, 2025 [5] - The company has a strong revenue stream, with reported revenues of 149 million yuan for the first half of 2025 [5] Group 4 - The company has a comprehensive product matrix covering all areas of orthopedics, including spinal, trauma, joint, and sports medicine [8] - Aide Technology emphasizes providing affordable and high-quality orthopedic products, focusing on grassroots medical markets [9] - The company has established a strong brand presence in the minimally invasive spinal treatment sector [9]

中国经济网北京11月22日讯 北京证券交易所上市委员会2025年第33次审议会议于2025年11月21 日上午召开，审议结果显示，苏州爱得科技发展股份有限公司（简称"爱得科技"）首发符合发行条件、 上市条件和信息披露要求。这是今年过会的第79家企业。 爱得科技的保荐机构为德邦证券股份有限公司，保荐代表人为吴金鑫、刘德新。这是德邦证券今年 保荐成功的第2单IPO项目。此前，4月11日，德邦证券保荐的岷山环能高科股份公司过会。 爱得科技主要从事以骨科耗材为主的医疗器械的研发、生产与销售，主要产品包括脊柱类、创伤 类、运动医学等骨科医用耗材以及用于伤口疗愈的创面修复产品。 截至招股说明书签署日，陆强直接持有爱得科技34.99%的股份，黄美玉直接持有爱得科技38.78% 的股份，同时通过苏州市禾禾稼企业管理有限公司控制爱得科技5.29%的股份，两人直接持有和控制的 公司股份比例共计79.07%；陆强与黄美玉系夫妻关系，二人为公司控股股东及实际控制人。 爱得科技拟向不特定合格投资者公开发行股票不少于100万股且不超过2,953.0762万股（含本数， 不含超额配售选择权）。公司及主承销商可以根据具体情况择机采用超额配售 ...

Group 1 - The stock price of Dabo Medical closed at 54.00 yuan on August 27, 2025, down by 3.86 yuan, a decrease of 6.67% from the previous trading day [1] - The trading volume on that day was 84,500 hands, with a total transaction amount of 466 million yuan [1] - Dabo Medical operates in the medical device industry, focusing on the research, production, and sales of orthopedic implant medical consumables [1] Group 2 - Dabo Medical's product range includes trauma, spine, and joint medical devices, with a market presence in both domestic and international regions [1] - The company announced that its shareholder, Dabo Medical International Investment Co., Ltd., plans to reduce its holdings by no more than 8.2804 million shares, accounting for 2.00% of the total share capital, between September 18 and December 17, 2025 [1] - The current shareholding ratio of the shareholder is 20.03%, and the reason for the reduction is due to personal asset allocation needs [1] Group 3 - On August 27, 2025, there was a net outflow of 73.4616 million yuan in main funds, with a cumulative net outflow of 136 million yuan over the past five days [1]

Core Viewpoint - The company, Dabo Medical, has shown significant growth in its financial performance for the first half of 2025, with notable increases in revenue and profit metrics, despite a slight decline in stock price on August 22, 2025 [1]. Financial Performance - For the first half of 2025, Dabo Medical achieved a revenue of 1.21 billion yuan, representing a year-on-year growth of 25.55% [1]. - The net profit attributable to shareholders reached 244 million yuan, marking a year-on-year increase of 76.69% [1]. - The net profit after deducting non-recurring items was 223 million yuan, reflecting an 82.64% year-on-year growth [1]. - The net cash flow from operating activities was 263 million yuan, which is a 96.3% increase compared to the previous year [1]. - Revenue from overseas business grew by 50.84%, contributing to 13.02% of total revenue [1]. Stock Performance - As of August 22, 2025, Dabo Medical's stock price was 58.41 yuan, down 0.15% from the previous trading day [1]. - The stock opened at 58.75 yuan, reached a high of 58.78 yuan, and a low of 57.51 yuan, with a trading volume of 286 million yuan and a fluctuation of 2.17% [1]. - On August 22, there was a net outflow of 44.22 million yuan in principal funds, accounting for 0.26% of the circulating market value [1]. - Over the past five days, the cumulative net outflow of principal funds was 149 million yuan, representing 0.88% of the circulating market value [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which has a current stock price of 23.29 yuan, a PE ratio of 69.87, and a total market capitalization of 8.933 billion yuan [1][2] - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, positioning Spring Medical at the 93rd rank within the industry [1][2] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, reflecting a year-on-year increase of 5.20%, with a gross margin of 66.69% [1]

Group 1 - The core viewpoint of the article highlights that Spring Medical's stock closed at 22.93 yuan, down 2.76%, with a rolling PE ratio of 68.79 times and a total market value of 8.795 billion yuan [1] - The average PE ratio for the medical device industry is 59.49 times, with a median of 40.19 times, placing Spring Medical at the 91st position in the industry ranking [1] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]

Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - Chuangli Medical's A/H share premium reached 52.01%, ranking 67th among A/H shares [1] - On the closing day, Chuangli Medical's A-shares were priced at 23.58 yuan, down 0.8%, and H-shares at 16.9 HKD, up 0.18% [1] Group 2 - Chuangli Medical, established in 1998, focuses on the continuous development and research of high-end medical devices, covering a full range of orthopedic products including joint, spine, sports medicine, and trauma categories [1] - The company has obtained 124 medical device registration certificates and filings, enhancing its product line and expanding its presence in the medical field [1] - Chuangli Medical maintains a leading position in the domestic market while actively exploring international markets, with products exported to over 50 countries and regions worldwide [1]

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 23.77 yuan, with a PE ratio of 71.31 times, significantly higher than the industry average of 56.58 times [1][2] - As of March 31, 2025, Chunzhi Medical had 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan per shareholder [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, and bone repair materials [1] Group 2 - In the latest quarterly report for Q1 2025, Chunzhi Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, up 5.20% year-on-year, with a gross margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, positioning Chunzhi Medical at the 92nd rank within the industry [1][2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which has a current stock price of 23.33 yuan, down 6.94%, with a rolling PE ratio of 69.99 times and a total market value of 8.949 billion yuan [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Spring Medical at the 92nd position in the industry ranking [1] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1] - The company has been recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]